[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intracerebral-hemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intracerebral-hemorrhage":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,72,0,25,[9,52,76,105,129,157,179,207,240,270,290,315,335,357,382,405,431,455,481,501,522,549,573,602,636],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100377049","improving-outcomes-for-patients-with-life-threatening-neurologic-illness-100377049",false,"NCT04189471","Improving Outcomes for Patients With Life-Threatening Neurologic Illness","Recovery After Cerebral Hemorrhage--Improving Outcomes for Patients With Life-Threatening Neurologic Illness","REACH","Inclusion Criteria:\n\n* clinical diagnosis of potentially life-threatening neurological illness\n* admitted to Neuro ICU within 14 days of initial injury\n\nExclusion Criteria:\n\n* known pre-existing neurological deficits related to a developmental disorder\n* prior severe stroke\n* prior severe dementia\n* prior severe head injury\n* prisoners","ALL","18 Years",{"count":21,"type":22},5000,"ESTIMATED","12 Months","OBSERVATIONAL","Background:\n\nWhile the intensive care of patients with life-threatening brain illnesses has advanced tremendously, a large number of therapies are still without proper scientific support.\n\nThis can be partly explained by the fact that mechanisms of initial brain injury are still not well understood. Why additional neurological injury occurs during a patient's stay in the NeuroCritical Care Unit (NCCU) despite current best, evidence-based clinical practices, is also not well understood. However, over the past decade, better tools have become available to measure and monitor the impact of our clinical care on the rapidly changing physiology and chemistry of the injured brain. Some of these tools are CT, MRI, ultrasound, and catheter-based technology measuring blood flow and metabolism. These tools have enabled earlier detection of injury and complications and newer therapeutic strategies.\n\nPurpose:\n\nExamine disease pathways common to all brain injuries seen in the University of Maryland's 22-bed NCCU. Life-threatening neurological illnesses cared for in the NCCU include massive stroke, bleeding in and around the brain (subarachnoid hemorrhage, intracerebral hemorrhage, subdural hemorrhage, intraventricular hemorrhage), brain tumors, difficult to control seizures, neurologic infections, nerve and muscle diseases (such as myasthenia gravis or Guillain-Barre Syndrome), and spinal cord disorders among others. Many NCCU patients are comatose or paralyzed and may suffer injuries in other parts of the body as well.\n\nThis effort will require the creation of a robust clinical database for the capture of data including patient characteristics (age, sex), clinical characteristics, medical treatments, surgical interventions, physiological data (such as vital signs, cerebral blood flow, intracranial pressure, cerebral oximetry, etc), laboratory data, and standard-of-care diagnostic studies such as electroencephalography (EEG), ultrasound, CT, MRI, and angiograms. Similar databases exist at other major centers for neurocritical care and have been instrumental to the identification of characteristics both predictive of and associated with outcomes of patients long after their stay in the NCCU.\n\nIn addition, the samples collected will be included in the University of Maryland Medicine (UMM) Biorepository which is a shared resource to enable biomedical research by University of Maryland faculty.",[27,28,29,30,31],"Intracerebral Hemorrhage","Subarachnoid Hemorrhage","Intraventricular Hemorrhage","Nontraumatic Haemorrhage","Status Epilepticus",[33,34,35,30,36,37,38],"hemorrhage","intracerebral hemorrhage","SAH","ICH","subarachnoid hemorrhage","status epilepticus","RECRUITING","2026-06-30",{"date":42,"type":43},"2026-07-02","ACTUAL",{"date":45,"type":43},"2014-09-08",{"date":47,"type":22},"2034-01-01",{"name":49,"class":50},"University of Maryland, Baltimore","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100547053","clevidipine-for-the-antihypertensive-treatment-of-acute-intracerebral-hemorrhage-100547053","NCT06402968","Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage","CLUTCH","Inclusion Criteria\n\n1. Age 18 years or older and less than 100 years.\n2. Onset of new neurological deficits within 12 hours at the time of enrollment and IV clevidipine or alternate IV antihypertensive regimen can be initiated within 12 hours of symptom onset.\n3. Clinical signs consistent with the diagnosis of stroke, including impairment of language, motor function, cognition, and\u002For gaze, vision, or neglect.\n4. Initial National Institutes of Health Stroke Scale (NIHSS) score of 1 or greater.\n5. Total GCS score (aggregate of verbal, eye, and motor response scores) of 5 or greater at enrollment\n6. Computed Tomography (CT) scan of the brain demonstrates intraparenchymal hematoma with manual hematoma volume measurement \\>5 cc (excluding microhemorrhages)\n7. Admission SBP greater than and equal to 150 mmHg but less than 220 mmHg on two repeat measurements at least 5 minutes apart, but no more than 10 minutes apart. The reason for exclusion of ICH patients with initial SBP ≥220 mm Hg is based on a post hoc analysis of ATACH-2, which found that patients with initial SBP ≥220 mm Hg (22.8% of the cohort) reported higher rates of neurological deterioration at 24 hours and renal adverse events until day 7 or discharge in patients treated with intensive SBP reduction compared with standard SBP lowering, without any benefit in reducing hematoma expansion at 24 hours or death or severe disability at 90 days.\n8. Signed and dated informed consent by subject, legally authorized representative, or surrogate before index hospital discharge for data collection and agreement to participate in 90- and 180-day follow-up visits.\n9. Patients with anticoagulant-related ICH are eligible as long as anticoagulant reversal is concurrently undertaken consistent with AHA\u002FASA guidelines.\n10. Patients who will undergo surgical evacuation consistent with AHA\u002FASA guidelines or local institutional guidelines are eligible unless surgical evacuation is being performed within 6 hours of initiation of IV clevidipine or alternate IV antihypertensive medication regimen. Ultra-early surgery will necessitate use of anesthetic agents which will confound the effect of IV clevidipine or alternate IV antihypertensive medication regimen. Ultra-early surgery\u002Fintervention was not used in the minimally invasive catheter evacuation followed by thrombolysis (MISTIE)\u002F Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage (CLEAR) trials, which required ICH patients to undergo a repeat CT scan after 6 hours to document absence of any hematoma expansion (with ≤5 mL hematoma growth) compared to a previous CT scan prior to any surgical intervention.\n11. Patients requiring external ventricular drainage consistent with AHA\u002FASA guidelines or local institutional guidelines are eligible.\n\nExclusion Criteria\n\n1. Time of symptom onset cannot be reliably assessed.\n2. Previously known neoplasms, arteriovenous malformation (AVM), or aneurysms.\n3. Intracerebral hematoma considered to be related to trauma.\n4. ICH located in infratentorial regions such as pons or midbrain (cerebellar ICH is not an exclusion criteria).\n5. Subject considered a candidate for immediate surgical intervention by the neurosurgery service.\n6. Pregnancy, parturition within previous 30 days, or active lactation.\n7. Any history of bleeding diathesis or coagulopathy except anticoagulant related ICH.\n8. Platelet count of less than 50,000\u002Fmm3.\n9. Known sensitivity to nicardipine or clevidipine.\n10. Patient's living will precludes aggressive ICU management.\n11. Patients with allergies to soybeans, soy products, eggs, or egg products.\n12. Defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia.\n13. Patients with severe aortic stenosis.","100 Years",{"count":61,"type":22},1000,"The aim is to compare the rate of hypertensive subjects with ICH who reach SBP target with stability within 60 minutes of enrollment, among patients treated with IV clevidipine with those treated with alternate IV antihypertensive regimen.",[27,64,65],"Stroke","Hypertension","2026-06-25",{"date":68,"type":43},"2026-06-26",{"date":70,"type":43},"2024-06-01",{"date":72,"type":22},"2028-07-30",{"name":74,"class":50},"Zeenat Qureshi Stroke Institute",16,{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":85,"targetDuration":87,"studyType":24,"phases":4,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100644160","cirp-and-cathepsin-b-in-neuroinflammation-after-intracerebral-hemorrhage-100644160","NCT07665255","CIRP and Cathepsin B in Neuroinflammation After Intracerebral Hemorrhage","A Prospective Observational Case-Control Study of Peripheral Blood CIRP, Cathepsin B, and Related Inflammatory Biomarkers in Patients With Intracerebral Hemorrhage","CIRP-ICH","Inclusion Criteria:\n\nIntracerebral hemorrhage group:\n\nAge 18 years or older Diagnosis of intracerebral hemorrhage confirmed by head CT or MRI Supratentorial hemorrhage No surgical treatment Hematoma volume less than 30 mL Admission within 24 hours after symptom onset The participant or the legally authorized representative\u002Fnext of kin is able to provide written informed consent\n\nHealthy control group:\n\nAge 18 years or older Recruited from the hospital health examination center No history of stroke, intracerebral hemorrhage, cerebral infarction, or other major neurological diseases No severe active infection, severe immune disease, hematologic disease, or end-stage severe heart, liver, or renal failure No acute infection, trauma, or other obvious stress state within the previous 2 weeks Able to provide written informed consent\n\nExclusion Criteria:\n\nIntracerebral hemorrhage group:\n\nTraumatic intracerebral hemorrhage Secondary intracerebral hemorrhage caused by brain tumor, cerebrovascular malformation, aneurysm, or hemorrhagic transformation of infarction Severe active infection, severe immune disease, or hematologic disease End-stage severe heart, liver, or renal failure Pregnant or lactating women Any other condition judged unsuitable by the investigator\n\nHealthy control group:\n\nHistory of stroke, intracranial hemorrhage, brain tumor, or other major neurological diseases Severe active infection, severe immune disease, or hematologic disease End-stage severe heart, liver, or renal failure Pregnant or lactating women Any other condition judged unsuitable by the investigator",true,{"count":86,"type":22},60,"1 Day","This is a single-center, investigator-initiated, prospective observational case-control study. Patients with intracerebral hemorrhage and healthy controls will be enrolled at Xuanwu Hospital, Capital Medical University. Peripheral venous blood samples will be collected for measurement of CIRP, Cathepsin B, and related inflammatory biomarkers. Clinical and imaging data will also be collected in the intracerebral hemorrhage group. The study aims to compare biomarker levels between patients with intracerebral hemorrhage and healthy controls and to explore the potential role of these biomarkers in neuroinflammation after intracerebral hemorrhage. No investigational treatment will be administered.",[27,90],"Nontraumatic Intracerebral Hemorrhage",[92,93,94],"Neuroinflammation","cirp","Cathepsin B","NOT_YET_RECRUITING","2026-06-22",{"date":98,"type":43},"2026-06-24",{"date":100,"type":22},"2026-07-01",{"date":102,"type":22},"2028-12-31",{"name":104,"class":50},"Xuanwu Hospital, Beijing",{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":16,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":51},"100642204","rapid-evacuation-and-access-of-cerebral-hemorrhage-registry-100642204","NCT07651631","Rapid Evacuation and Access of Cerebral Hemorrhage Registry","A Prospective, Multicenter, Global Registry Evaluating Minimally Invasive Surgery for the Treatment of Acute Spontaneous Supratentorial Intracerebral Hemorrhage.","Inclusion Criteria:\n\n* Head CT demonstrating an acute, spontaneous, intracerebral hemorrhage\n* Hemorrhage volume ≥ 20 mLs\n* Minimally invasive surgical intervention performed within 7 days of hemorrhage\n\nExclusion Criteria:\n\n* Ruptured aneurysm, arteriovenous malformation (AVM), vascular anomaly, moyamoya disease, venous sinus thrombosis, mass or tumor, hemorrhagic conversion of an ischemic infarct, recurrence of a recent ICH (\\\u003C1 year), as diagnosed with radiographic imaging\n* Infratentorial intraparenchymal hemorrhage, including midbrain, pontine, or cerebellum\n* Initial hospital arrival ≥ 24 hours after the onset of stroke symptoms\n* Last known normal is unknown\n* Historical Modified Rankin Score \\> 4\n* Known life-expectancy of less than 1 year prior to ICH\n* DNR or comfort measures only\n* Known pregnancy in female subjects\n* Inability or unwillingness of subject or legal guardian\u002Frepresentative to give written informed consent within 7 days of initial hospital arrival\n* Inability to meet follow up requiremen",{"count":113,"type":22},2500,"The goal of this observational study is to quantify the real-world effect of minimally invasive surgery (MIS) in patients with acute spontaneous supratentorial intracerebral hemorrhage.",[27],[27,117,118,119],"ICH is the basal ganglia","modified Rankin Scale","Arteriovenous Malformation","2026-06-11",{"date":122,"type":43},"2026-06-16",{"date":124,"type":22},"2026-06",{"date":126,"type":22},"2033-06",{"name":128,"class":50},"Emory University",{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":140,"phases":141,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":51},"100616161","targeted-temperature-management-via-bladder-monitoring-in-ich-100616161","NCT07302009","Targeted Temperature Management Via Bladder Monitoring in ICH","Safety and Efficacy of Bladder Temperature Monitoring-Guided Targeted Temperature Management in Patients With Severe : A Multicenter Randomized Controlled Trial","BTTM-ICH","Inclusion Criteria:\n\n1. Neurocritical care patients: Study subjects are patients with first-time spontaneous intracerebral hemorrhage.\n2. Age ≥ 18 years and ≤ 85 years.\n3. Glasgow Coma Scale (GCS) score ≤ 8 at ICU admission.\n4. For supratentorial ICH: Hematoma volume \\\u003C 60 mL. For subarachnoid hemorrhage (SAH): Modified Fisher grade ≥ 2, and the aneurysm has been treated with endovascular intervention.\n5. Pre-morbid modified Rankin Scale (mRS) score of 0 or 1.\n6. Signed informed consent provided by a legally authorized representative.\n\nExclusion Criteria:\n\n1. Fever (≥38.0°C) that lasted over 1 hour or occurred more than once prior to enrollment.\n2. Pre-existing neurological, psychiatric, or other comorbidities that may compromise the assessment of neurological or functional outcomes.\n3. Underlying conditions with a life expectancy of less than 6 months, estimated prior to onset.\n4. Severe injury indicative of poor prognosis: brain death, receiving palliative care only, or irreversible brain injury.\n5. Pregnancy.\n6. Unilateral or bilateral pupillary dilation.\n7. Currently participating in other investigational\u002Finterventional clinical trials (involving medical devices or drugs).\n8. Subjects deemed ineligible for enrollment by the investigator.","85 Years",{"count":139,"type":22},318,"INTERVENTIONAL",[142],"NA","The goal of this clinical trial is to learn whether a bladder temperature monitoring-guided targeted temperature management (TTM) strategy improves functional recovery in patients with severe intracerebral hemorrhage, compared to conventional temperature monitoring. It will also assess the safety of this monitoring approach. The main questions it aims to answer are:\n\n* Does continuous bladder temperature monitoring-guided TTM improve the likelihood of a favorable functional outcome (modified Rankin Scale score 0-2) at 180 days after onset?\n* What medical problems (such as infections, shivering, deep vein thrombosis, or sepsis) do participants experience while under the TTM strategy? Researchers will compare the intervention group (using continuous bladder temperature monitoring) with the control group (using conventional intermittent temperature monitoring with a mercury thermometer at the armpit) to see if the bladder temperature-guided TTM strategy leads to better outcomes.\n\nParticipants will:\n\n* Be randomly assigned to one of the two temperature monitoring strategies\n* Receive standard medical and surgical care for severe intracerebral hemorrhage",[27,145],"Targeted Temperature Management",[27,145,147],"Bladder Temperature Monitoring","2026-06-07",{"date":150,"type":43},"2026-06-10",{"date":152,"type":43},"2026-03-15",{"date":154,"type":22},"2027-12-30",{"name":156,"class":50},"Yanyan Gong",{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":59,"enrollmentInfo":164,"targetDuration":4,"studyType":140,"phases":166,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":176,"locationsCount":178},"100638500","phase-2-glp-1-receptor-agonist-in-primary-intracerebral-hemorrhage-a-phase-2-randomized-trial-100638500","NCT07613437","GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial","GLICH","Inclusion Criteria:\n\n* 1\\. Primary spontaneous ICH with hematoma location in putamen (10-30mL) or thalamus (5-15mL) on admission CT imaging. Both locations are selected because they are strongly associated with hypertensive arteriopathy-related ICH and there is limited evidence supporting neurosurgical intervention compared with posterior fossa hemorrhages. The thalamic and putaminal volume cutoffs are based on a recent observational study showing that restricting enrolment to 5-15 mL (thalamus) and 10-30 mL (putamen) enriches for patients with substantial but potentially modifiable prognosis while avoiding extremes with ceiling or floor effects. For patients with hematoma involving both putamen and thalamus, a volume cutoff of 5-30mL will be used.\n* 2\\. National Institutes of Health Stroke Scale (NIHSS) score ≥ 6 AND ≤ 25 at presentation\n* 3\\. Glasgow Coma Scale (GCS) score ≥ 10\n* 4\\. Last-known-well (LKW) to presentation time ≤ 24 hours\n* 5\\. Pre-stroke modified Rankin Scale (mRS) ≤ 2\n* 6\\. Patients deemed not suitable for acute neurosurgical intervention at the time of randomization\n* 7\\. Informed consent obtained from patient (if mentally competent) or legal representative, as per national laws, regulations, and applicable ethics committee requirements\n\nExclusion Criteria:\n\n* 1\\. Secondary ICH: ICH due to macrovascular abnormalities (e.g., arteriovenous malformation, aneurysm, arterial dissection, cavernous malformation), coagulopathy, anticoagulant use, antiplatelet overdose, or thrombocytopenia.\n* 2\\. ICH involving locations other than putamen or thalamus (e.g., lobar, brainstem, cerebellar, isolated intraventricular hemorrhage). Extension of hematoma into other structures is allowed if the hematoma centroid is within the thalamus or putamen, and the hematoma volume does not exist the respective thresholds as stated in Inclusion Criterion 1.\n* 3\\. ICH with planned neurosurgical procedure prior to randomization, including hematoma evacuation, external ventricular drainage and decompressive craniectomy.\n* 4\\. Estimated or known body mass index (BMI) \\\u003C 18 kg\u002Fm².\n* 5\\. Pregnancy, lactation, or positive urine or serum beta human chorionic gonadotropin (β-hCG) test. β-hCG testing should be guided by clinical need.\n* 6\\. Creatinine clearance \\\u003C 30 mL\u002Fmin (estimated by Cockcroft-Gault equation or measured)\n* 7\\. Severe or fatal comorbid illness with life expectancy \\\u003C 3 years (e.g., terminal malignancy, advanced organ failure)\n* 8\\. Participation in another clinical trial investigating a drug, medical device, or medical procedure within 30 days preceding trial inclusion.\n* 9\\. Known history of allergy or hypersensitivity to GLP-1RA.\n* 10\\. Family or personal history of multiple endocrine neoplasia (MEN), medullary thyroid carcinoma, or pancreatic carcinoma\n* 11\\. Active sepsis at time of randomization, defined as a body temperature of ≥ 38.5C, or suspected or documented infection and acute organ dysfunction, operationalized as an increase in SOFA score ≥ 2 points from baseline (baseline assumed 0 if no pre-existing organ dysfunction)\n* 12\\. Contraindications to proposed imaging studies (e.g., pacemaker incompatibility with MRI where applicable)",{"count":165,"type":22},200,[167],"PHASE2","Intracerebral hemorrhage (ICH) is a devastating form of acute stroke with poor clinical outcomes. Although ICH accounted only for 28.8% of incident strokes, it was responsible for nearly half of the long-term burden of stroke measured in disability-adjusted life years . In contrast to the improving outcomes seen in ischemic stroke with advances in reperfusion therapy, outcomes of patients with ICH have shown little progress over the past two decades. Current standard care focuses primarily on blood pressure control and supportive management, yet rate of functional independence remained modest. Randomized evidence suggested that fewer than half of the ICH patients achieved independent activities of daily living even with intensive blood pressure lowering.\n\nA cascade of pathophysiological events is thought to determine the prognosis of ICH. First, the mass effect of the hematoma and its expansion with uncontrolled blood pressure cause primary neuronal injury. Second, neuroinflammation involving blood-brain barrier (BBB) dysfunction, activated microglia and astrocytes, together with neutrophil infiltration in response to extravascular blood, propagates neuronal injury, leading to perihematomal edema. Third, the direct neurotoxicity of blood breakdown products and oxidative stress may further amplify neuroinflammation. Mitigating hematoma expansion through intensive blood pressure control therefore only addresses one of these three pathophysiological processes, and is constrained by a short treatment window, mostly within 6 hours. Therapeutic strategies targeting secondary neuroinflammation should therefore be actively pursued. In addition, multimodal studies incorporating longitudinal imaging and omics markers are needed to elucidate the key pathways mediating neuroinflammation following ICH.\n\nRecent preclinical evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RA) may offer neuroprotective benefits in ICH. In animal models of ICH, intracerebroventricular liraglutide suppressed neuroinflammation, prevented brain edema, and reduced neurologic deficits. Previous work from our group has also shown that, across several animal models, GLP-1RA attenuates BBB dysfunction and suppresses neuroinflammatory signaling via microglial modulation. Importantly, a recent translational clinical trial by our team has also provided preliminary evidence that GLP-1RA exerts neuroprotective effects in patients with large vessel occlusion strokes. We therefore hypothesize that compared to standard therapy, administration of GLP-1RA in patients with primary ICH may limit perihaematomal edema, reduce secondary brain injury, and improve neurological outcomes.\n\nIn this phase 2, randomized, open-label pilot study with blinded endpoint assessment, we aim to determine the safety and signals for efficacy of GLP-1RA in patients with primary ICH.",[27],"2026-05-22",{"date":172,"type":43},"2026-05-29",{"date":174,"type":22},"2026-06-15",{"date":102,"type":22},{"name":177,"class":50},"Chinese University of Hong Kong",3,{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":140,"phases":189,"briefSummary":191,"conditions":192,"keywords":195,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":4},"100639201","phase-4-oral-anticoagulation-after-stroke-with-prior-ich-in-subjects-with-af-100639201","NCT07609654","Oral Anticoagulation After Stroke With Prior ICH in Subjects With AF","A Prospective, Multicenter, Randomized Controlled Trial of Anticoagulation Therapy After Ischemic Stroke in Patients With Previous Intracerebral Hemorrhage and Atrial Fibrillation","OASIS-AF","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Diagnosis of acute ischemic stroke, with no evidence of hemorrhagic transformation confirmed by acute neuroimaging (MRI and CT).\n3. Documented history of spontaneous intracerebral hemorrhage (ICH).\n4. Confirmed non-valvular atrial fibrillation (including paroxysmal, persistent, or permanent subtypes).\n5. Provision of written informed consent by the patient or a legally authorized representative.\n\nExclusion Criteria:\n\n1. Severe baseline disability, defined as a pre-stroke Modified Rankin Scale (mRS) score \\> 4.\n2. Intracerebral hemorrhage definitively caused by underlying structural vascular lesions (e.g., AVM, aneurysm) or systemic diseases.\n3. Severe, uncontrolled hypertension refractory to medical therapy.\n4. Severe renal impairment, defined as an estimated Creatinine Clearance (CrCl) \\\u003C 30 mL\u002Fmin.\n5. Clinical indications necessitating continuous oral anticoagulation therapy other than atrial fibrillation (e.g., mechanical prosthetic heart valves, deep vein thrombosis, pulmonary embolism).\n6. Documented contraindications to direct oral anticoagulants according to the product summary of characteristics (excluding the previous spontaneous ICH), including but not limited to hypersensitivity, active clinically significant bleeding, high-risk bleeding lesions, or hepatic disease associated with coagulopathy and clinically relevant bleeding risk.\n7. Prior deployment of, or planned procedure for, a left atrial appendage occlusion (LAAO) device.\n8. Women who are pregnant, breastfeeding, or planning to become pregnant during the trial period.\n9. Estimated life expectancy of less than 1 year due to concomitant terminal illness.",{"count":188,"type":22},852,[190],"PHASE4","This prospective, multicenter, randomized controlled trial aims to evaluate the efficacy and safety of initiating direct oral anticoagulants (DOACs) in patients with a history of spontaneous intracerebral hemorrhage (ICH) and non-valvular atrial fibrillation (AF) who have recently suffered an acute ischemic stroke. Existing evidence regarding the optimal antithrombotic strategy for this specific high-risk \"double-jeopardy\" population remains largely undefined. Eligible participants will be randomized in a 1:1 ratio to either receive oral anticoagulation therapy or a non-anticoagulation standard of care. The primary objective is to assess the incidence of a composite endpoint consisting of recurrent ischemic stroke and recurrent ICH over a 12-month follow-up period.",[193,27,194],"Acute Ischemic Stroke","Atrial Fibrillation (AF)",[193,27,194,196,197],"DOACs","Anticoagulation","2026-05-20",{"date":200,"type":43},"2026-05-27",{"date":202,"type":22},"2026-06-01",{"date":204,"type":22},"2029-09-01",{"name":206,"class":50},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":140,"phases":217,"briefSummary":218,"conditions":219,"keywords":222,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":239},"100549078","phase-4-international-care-bundle-evaluation-in-cerebral-hemorrhage-research-100549078","NCT06429332","International Care Bundle Evaluation in Cerebral Hemorrhage Research","International Care Bundle Evaluation in Cerebral Hemorrhage Research - a Batched Parallel Cluster-randomized Trial With a Baseline Period","I-CATCHER","Inclusion Criteria:\n\n* Adults (age ≥18 years)\n* Non-contrast computerized tomography (NCCT) imaging-verified diagnosis of spontaneous intracerebral haemorrhage\n* ≤24 hours from symptom onset or presumed symptom onset (last seen well)\n\nExclusion Criteria:\n\n* Previous care limitation\n* End-stage comorbidity with short life-expectancy (\\\u003C6 m; e.g. terminal cancer)\n* ICH caused by brain tumor or cerebral venous thrombosis\n* Clinical signs of brain herniation at first presentation (unresponsive patient with bilaterally fixed, maximally dilated pupils)\n* Pregnant women beyond 22 weeks gestation may only be included after thorough discussion with an obstetrician to determine risks vs benefit.",{"count":216,"type":22},3500,[190],"Spontaneous intracerebral haemorrhage (ICH) accounts for approximately 10-15% of all strokes but stands for 50% of stroke-related morbidity and mortality. Approximately half of all patients with ICH have a decreased level of consciousness at hospital admission. Despite this, intensive care and neurosurgical interventions are uncommon. A study conducted in low- and middle-income countries has demonstrated a beneficial effect of a treatment package consisting of early intensive blood pressure lowering, as well as the treatment of pyrexia and elevated blood glucose levels. The I-CATCHER team is now planning to conduct a similar study in Sweden and Australia, as well as in other high-income countries. The study has a clear focus on implementation, aiming to improve treatment and prognosis for patients with ICH within a few years. The purpose of I-CATCHER is to investigate whether a structured treatment package (Care Bundle) improves 3-month prognosis in patients with spontaneous ICH compared to standard care.",[27,220,29,64,221],"Intracerebral Haemorrhage","Cerebrovascular Disease",[34,223,224,225,226,227,228,229,230,231],"oral anticoagulant","blood pressure lowering","early intensive blood pressure lowering","care bundle","implementation study","reversal treatment","outcome","UW-mRS","Modified Rankin Scale",{"date":170,"type":43},{"date":234,"type":43},"2025-01-07",{"date":236,"type":22},"2027-07",{"name":238,"class":50},"Region Skane",54,{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":84,"sex":18,"minAge":19,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":251,"conditions":252,"keywords":255,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":51},"100624549","ex-vivo-reproduction-of-minimally-invasive-surgery-with-hematoma-lysis-using-modified-tissue-plasminogen-activator-for-intracerebral-hemorrhage-100624549","NCT07411079","Ex Vivo Reproduction of Minimally Invasive Surgery With Hematoma Lysis Using Modified Tissue Plasminogen Activator for Intracerebral Hemorrhage","Ex Vivo Reproduction of Minimally Invasive Surgery With Hematoma Lysis Using Modified Tissue Plasminogen Activator to Improve Parenchymal Clearance in Intracerebral Hemorrhage","MIMICK-TIPITCH","Inclusion Criteria:\n\n* Adult participants (≥ 18 years of age)\n* Able and willing to provide written informed consent\n* Receiving routine outpatient care\n* Either:\n* Without identified hemorrhagic risk (control subjects)\n* With a predefined hemorrhagic risk profile, including antithrombotic treatment, inherited bleeding disorders, thrombocytopenia or conditions requiring reversal or correction of coagulation abnormalities\n* Able to undergo a single additional whole blood collection (30 mL) during a routine clinical visit\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Inability or unwillingness to provide written informed consent\n* Contraindication to venipuncture or blood sampling\n* Known human immunodeficiency virus (HIV) infection\n* Breastfeeding\n* Presence of an additional coagulation abnormality not related to the identified hereditary bleeding disorder or the antithrombotic treatment under study\n* Individuals deprived of liberty by judicial or administrative decision\n* Individuals under legal protection (guardianship or curatorship)","65 Years",{"count":250,"type":22},1126,"Intracerebral hemorrhage (ICH) is associated with high mortality and long-term disability, and effective treatment options remain limited. Minimally invasive surgical approaches combined with local administration of thrombolytic agents have been investigated to facilitate hematoma evacuation; however, incomplete clot removal remains frequent, particularly in patients with conditions associated with increased hemorrhagic risk.\n\nThis observational, cross-sectional study uses an ex vivo model of clinically sized intracerebral hematomas generated from whole blood samples collected from control subjects without hemorrhagic risk and from individuals with predefined hemorrhagic risk profiles, including conditions associated with antithrombotic treatment, inherited bleeding disorders, thrombocytopenia and situations involving reversal or correction of coagulation abnormalities.\n\nUsing standardized ex vivo hematoma formation and catheter-based administration of modified Tissue Plasminogen Activator (rtPA), the study will characterize clot structure, composition, and permeability across hemorrhagic risk conditions. The study will then determine personalized dosing regimens of modified rtPA in conditions where thrombolytic activity differs from reference values observed in healthy control samples treated with a standard dose. Finally, the thrombolytic activity of personalized dosing regimens will be evaluated by measuring hematoma weight reduction 9 hours after treatment and compared with predefined efficacy and safety reference boundaries.\n\nThe results of this study are intended to improve understanding of the ex vivo thrombolytic performance of modified rtPA across different hemorrhagic risk contexts and to support future translational and clinical research in intracerebral hemorrhage.",[27,253,254],"Hemorrhagic Risk Conditions","Bleeding Disorders",[256,257,258,254,259,260],"Intracranial Hemorrhages","Hematoma Lysis","Modified Tissue Plasminogen Activator","Antithrombotic Therapy","Ex vivo Model","2026-05-18",{"date":263,"type":43},"2026-05-19",{"date":265,"type":43},"2026-03-02",{"date":267,"type":22},"2029-03",{"name":269,"class":50},"University Hospital, Lille",{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":286,"leadSponsor":288,"locationsCount":4},"100640711","prospective-italian-validation-of-sms-in-patients-with-suspected-acute-stroke-100640711","NCT07601659","Prospective Italian Validation of SMS in Patients With Suspected Acute Stroke","Prospective Italian Multicenter Study for the Validation of the Stroke Mimics Score (SMS) in Patients With Suspected Acute Stroke","PIVA-SMS","Inclusion Criteria:\n\n* Age ≥ 18 years at the time of presentation to the Emergency Department.\n* Presentation to the Emergency Department with a clinical suspicion of acute stroke, identified at nursing triage and\u002For through activation of the stroke pathway.\n* Presentation to the Emergency Department during the 6-month prospective enrollment period.\n* Feasibility of real-time collection of the data required to calculate the Stroke Mimics Score (SMS), including:\n\nage, systolic blood pressure, presence\u002Fabsence of seizure at onset, presence\u002Fabsence of headache at onset, presence\u002Fabsence of confusion at onset, presence\u002Fabsence of syncope at onset, presence\u002Fabsence of isolated sensory deficit, presence\u002Fabsence of motor deficit, history of coronary artery disease, history of prior stroke or transient ischemic attack (TIA).\n\n* Availability of a final hospital discharge diagnosis at the end of hospitalization or Emergency Department observation.\n* Signed informed consent from the patient or caregiver. If the patient is unconscious upon arrival at the Emergency Department, deferred consent will be applied.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Inability to fully collect the data required to calculate the Stroke Mimics Score (SMS).\n* Absence of a clearly defined final hospital discharge diagnosis.\n* Voluntary discharge, transfer, or death before completion of the diagnostic workup, in the absence of a reliable diagnosis.\n* Repeated Emergency Department visits for the same clinical event (only the first visit will be considered).",{"count":61,"type":22},"The overall objective of the study is to prospectively validate the diagnostic accuracy of the Stroke Mimics Score (SMS). This score is calculated using information collected at the time of the patient's arrival in the Emergency Department (triage) and may assist clinicians in distinguishing between:\n\n1. cerebrovascular events (ischemic stroke, intracerebral hemorrhage, and transient ischemic attack \\[TIA\\]),\n2. stroke mimics (i.e., conditions that present with stroke-like symptoms but without actual infarction of brain tissue).\n\nIn addition, the study aims to compare its results with other existing tools and to evaluate its performance across different patient groups.\n\nSpecifically, the present research seeks to generate data on the reliability of the SMS tool in providing an accurate diagnosis.",[281,193,27,282,64],"Cerebrovascular Event","TIA (Transient Ischemic Attack)","2026-05-15",{"date":170,"type":43},{"date":202,"type":22},{"date":287,"type":22},"2027-06-01",{"name":289,"class":50},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":140,"phases":300,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":314},"100355369","phase-3-anticoagulation-in-ich-survivors-for-stroke-prevention-and-recovery-100355369","NCT03907046","Anticoagulation in ICH Survivors for Stroke Prevention and Recovery","Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery","ASPIRE","Inclusion Criteria:\n\n* Age at least 18 years\n* Intracerebral hemorrhage (ICH) (including primary intraventricular hemorrhage) confirmed by brain CT or MRI\n* Can be randomized within 14-180 days after ICH onset\n* Non-valvular AF (defined as atrial fibrillation or atrial flutter), documented by electrocardiography or a physician-confirmed history of prior AF\n* Provision of signed and dated informed consent form by patient or legally authorized representative\n* For females of reproductive potential: use of highly effective contraception\n\nExclusion Criteria:\n\n* Index event is hemorrhagic transformation of a brain infarction or hemorrhage into a tumor\n* History of earlier ICH within 12 months preceding index event\n* Active infective endocarditis\n* Clear indication for anticoagulant drugs (e.g., requires anticoagulation for deep vein thrombosis or pulmonary embolism) or antiplatelet drugs (e.g., requires aspirin or clopidogrel for recent coronary stent).\n* Previous or planned left atrial appendage closure\n* Clinically significant bleeding diathesis\n* Serum creatinine ≥2.5 mg\u002FdL\n* Active hepatitis or hepatic insufficiency with Child-Pugh score B or C\n* Anemia (hemoglobin \\\u003C8 g\u002FdL) or thrombocytopenia (\\\u003C100 x 10\\^9\u002FL) that is chronic in the judgment of the investigator\n* Pregnant or breastfeeding\n* Known allergy to aspirin or apixaban\n* Concomitant participation in a competing trial\n* Considered by the investigator to have a condition that precludes safe or active participation in the trial\n* Persistent, uncontrolled systolic blood pressure (≥180 mm Hg)\n* ICH caused by an arteriovenous malformation (AVM) that has not yet been secured",{"count":299,"type":22},700,[301],"PHASE3","Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF).\n\nSecondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.",[27,304],"Atrial Fibrillation","2026-05-07",{"date":307,"type":43},"2026-05-08",{"date":309,"type":43},"2020-01-28",{"date":311,"type":22},"2027-04",{"name":313,"class":50},"Yale University",187,{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":140,"phases":324,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":331,"leadSponsor":333,"locationsCount":178},"100638955","phase-2-role-of-neuroinflammation-and-blood-brain-barrier-breakdown-in-intracerebral-hemorrhage-100638955","NCT07583147","Role of Neuroinflammation and Blood-Brain Barrier Breakdown in Intracerebral Hemorrhage.","INFINITE","Inclusion Criteria:\n\n1. Adults (≥ 18 years old);\n2. presenting with a symptomatic spontaneous supratentorial ICH;\n3. ICH within 48 hours after symptoms onset (or last seen well);\n4. ICH confirmed by brain imaging;\n5. Informed consent documented;\n6. Affiliated or beneficiary of social security scheme.\n\nExclusion Criteria:\n\n1. Massive ICH volume (≥ 60 ml) at admission;\n2. Severe coma (defined as a Glasgow Coma Scale score \\\u003C 6) at admission;\n3. Planned neurosurgical hematoma evacuation;\n4. Decision already taken for palliative care with withdrawal of active treatment;\n5. Pre-existing dependance defined as a mRS score ≥2 prior to ICH occurrence;\n6. Underlying secondary cause of ICH including macrovascular causes (brain arteriovenous malformation, intracranial aneurysm, dural arteriovenous fistula, cavernous malformation), brain tumour, cerebral venous thrombosis, hemorrhagic infarction. Patients taking oral anticoagulant can be included;\n7. TSPO genotyping demonstrating a low affinity binder profile,\n8. Unable to tolerate or contraindicated to brain MRI: medical material not MRI compatible, claustrophobia, known hypersensitivity to gadoteric acid, meglumin or any drug containing gadolinium;\n9. Estimated glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73 m 2\n10. Unable to tolerate or contraindicated to 18F-DPA714 PET: women who are pregnant or breastfeeding, claustrophobia, and known hypersensitivity to DPA-714;\n11. Use of Benzodiazepines within 7 days (within 6 weeks for prazepam, diazepam or clorazepate) preceding TSPO PET acquisition;\n12. Co-existing neuroinflammatory disease such as Multiple Sclerosis, Neuromyelitis optica, Neurosarcoidosis, autoimmune encephalitis, CNS vasculitis;\n13. Conditions requiring long-term immunosuppressive medication;\n14. Expected impossible follow-up or poor compliance;\n15. Patient under tutorship, curatorship, or legal protection.",{"count":323,"type":22},117,[167],"In this prospective, multicenter study of patients with acute spontaneous supratentorial Intracerebral Hemorrhage (ICH), each participant will have a standardized multimodal evaluation of neuroinflammation at 10 (±2) days after onset including translocator protein 18 kDa (TSPO) positron emission tomography (PET) using 18F-DPA-714 radioligand, BBB imaging using Dynamic contrast-enhanced (DCE)-MRI and a panel of pro-inflammatory and anti-inflammatory plasma biomarkers.",[27],"2026-05-06",{"date":329,"type":43},"2026-05-13",{"date":124,"type":22},{"date":332,"type":22},"2029-12",{"name":334,"class":50},"University Hospital, Toulouse",{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":140,"phases":345,"briefSummary":346,"conditions":347,"keywords":348,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":355,"locationsCount":51},"100627943","evaluating-a-prototype-ct-scan-for-ich-evacuation-100627943","NCT07455201","Evaluating a Prototype CT Scan for ICH Evacuation","Feasibility of the Utilization of Siemens Prototypes in Minimally Invasive ICH Evacuation Treatment","ICH-CTP II","Inclusion Criteria:\n\n* Patient ≥ 18 years old\n* Patient is planned to undergo minimally invasive hemorrhage evacuation at Mount Sinai West Hospital\n\nExclusion Criteria:\n\n* Patient is \\\u003C 18 years old\n* Patient is not planned to undergo minimally invasive hemorrhage evacuation at Mount Sinai West Hospital",{"count":344,"type":22},15,[142],"The aim of the project is to collect pre-procedural CT scans, intra-procedural post-evacuation scans as well as immediate post-procedural CT scans to evaluate and collect feedback of two Siemens prototypes: 1) perfusion prototype and 2) automatic hemorrhage detection prototype. The assessment of the prototypes, including its features will focus on the feasibility, usefulness as well as the potential clinical value add in minimally invasive ICH treatment.",[27],[349],"Minimally invasive hemorrhage evacuation","2026-05-05",{"date":327,"type":43},{"date":353,"type":43},"2025-10-31",{"date":102,"type":22},{"name":356,"class":50},"Icahn School of Medicine at Mount Sinai",{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":365,"enrollmentInfo":366,"targetDuration":4,"studyType":140,"phases":368,"briefSummary":369,"conditions":370,"keywords":371,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":51},"100628221","vitamin-d-for-acute-intracerebral-hemorrhage-100628221","NCT07458815","Vitamin D for Acute Intracerebral Hemorrhage","Vitamin D Treatment in IntraCerebal Hemorrhage To Enhance Hematoma Resolution (VICToHR): a Pilot Study","VICToHR","Inclusion Criteria:\n\n* Spontaneous ICH diagnosis\n* Age ≥ 18 years\n* Within 96 hours of ICH\n* Premorbid Modified Rankin Scale of ≤2\n* Supratentorial ICH\n* ICH volume ≥2 mL\n\nExclusion Criteria:\n\n* Expected life expectancy of \\\u003C1 year\n* Glasgow Coma Scale \\\u003C9\n* Anticipated surgical evacuation of hematoma\n* Inability to participate in follow-up activity\n* Hypercalcemia\n* Hyperphosphatemia\n* History of kidney stones\n* Bleeding tendency\n* Severe renal impairment\n* Severe liver impairment\n* Known contraindication or allergy to vitamin D","90 Years",{"count":367,"type":22},40,[142],"Intracerebral hemorrhage (ICH) is the most deadly and debilitating form of stroke. To date, effective treatment that could improve the functional outcome of ICH remained elusive. In a mice model of ICH, it was demonstrated that high dose Vitamin D (VitD) treatment enhanced hematoma resolution by promoting reparative macrophage differentiation and improved neurobehavioral performance in mice. Hence, this pilot study aimed to investigate the feasibility and safety of VitD treatment for ICH in human subjects.\n\nVICToHR is a prospective, randomized, open-label, blinded-endpoint (PROBE) trial. Participants will be randomized 1:1 to receive either VitD or standard care (control). The intervention group will receive VitD 4000 IU daily for 2 weeks, followed by 1000 IU daily for 24 weeks. The primary outcomes are the rate of hematoma resolution at 14 days and the incidence of hypercalcemia and VitD toxicity. Hematoma volume will be assessed by a neuroradiologist who is blinded to treatment allocation.",[27],[372,373],"Intracerebral hemorrhage","Vitamin D","2026-04-29",{"date":327,"type":43},{"date":377,"type":43},"2026-03-01",{"date":379,"type":22},"2028-02-28",{"name":381,"class":50},"The University of Hong Kong",{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":389,"enrollmentInfo":390,"targetDuration":4,"studyType":140,"phases":392,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":403,"locationsCount":4},"100569583","phase-1-tenecteplase-tnk-in-the-treatment-of-intracerebral-hemorrhage-ich-100569583","NCT06696131","Tenecteplase (TNK) in the Treatment of Intracerebral Hemorrhage (ICH)","TNK in ICH","Inclusion Criteria\n\n* Patient\u002Flegally authorized representative has signed the Informed Consent Form.\n* Ability to comply with the study protocol, in the investigator's judgment.\n* Patients 18 to 80 years of age with an ICH had occurred within 24 hours before admission.\n* Spontaneous supratentorial (basal ganglia, thalamus, lobar) ICH ≥30 mL measured utilizing the ABC\u002F2 method.\n* Subjects with a GCS score of 5-14.\n* NIHSS ≥6.\n* Stability CT scan done at least 6 hours after baseline CT showing clot stability (growth \\\u003C5 mL as measured by ABC\u002F2 method). If the hematoma volume measured on the stability CT scan increases by 5 mL or more, a second stability CT scan will be performed 12 hours later.\n* Sustained systolic blood pressure (SBP) \\\u003C180 mm Hg for six hours recorded closest to the time of drug administration.\n* Symptoms must be present less than 24 hours prior to baseline CT scan.\n* Baseline Rankin score of 0 or 1.\n\nExclusion Criteria\n\n* Presence of infratentorial parenchymal bleeding.\n* Presence of a hemorrhage extending to the midbrain.\n* An unknown time of onset or the symptoms onset more than 24 hours prior to admission.\n* Pregnancy.\n* Inability to obtain written informed consent from subject or legal representative.\n* Sustained SBP \\>180 mm Hg for six hours recorded closest to the time of drug administration.\n* Age \\\u003C18 and \\>80 years.\n* Radiological evidence of arterio-venous malformation, aneurysm, amyloid angiopathy, Moyamoya disease, hemorrhagic conversion of an ischemic stroke, recurrent hemorrhage in the same location within the past 365 year or unstable mass as a source for the ICH.\n* Evidence of coagulopathy (international normalized ratio \\>1.3; platelet count \\\u003C100 ,000 or platelet dysfunction P2Y-12 \\>250) or known clotting disorder.\n* Bilateral fixed, dilated pupils indicating irreversible impaired brain stem function with GCS ≤4.\n* Patients with severe ICH and IVH who require an external ventricular drain (EVD) placement for cerebrospinal fluid (CSF) diversion or separate intraventricular thrombolysis.\n* Inability to maintain INR less than 1.3.\n* Use of anticoagulants prior to symptom onset and subjects requiring long-term anticoagulants (the reversal is permitted if the patient can tolerate the short-term risk of reversal).\n* Use of Dabigatran, Apixaban, and\u002For Rivaroxaban (or a similar medication from the similar medication class) prior to symptom onset.\n* Internal bleeding (GI, renal, respiratory etc).\n* Mechanical heart valve (Bioprosthetic heart valve is permitted).\n* Known risk for embolization, including history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis (atrial fibrillation without mitral stenosis is permitted).\n* Allergy or sensitivity to TNKase.\n* Participation in a concurrent clinical trial.\n* Serious illness (advanced stage which can interfere with the outcome).\n* The patient is unstable and would not benefit from a surgical intervention.\n* GCS score of 3-4 and 15 (to ensure patient safety and study feasibility).\n* Historical mRS score of 2-6 (at admission).\n* Symptomatic tract hemorrhage or a tract hemorrhage more than 5 mm.","80 Years",{"count":391,"type":22},5,[393],"PHASE1","The overall purpose of this study is to look at the safety and effectiveness of administering Tenecteplase (TNK) into the brain bleed (hematoma) instead of another clot-dissolving drug known as recombinant tissue plasminogen activator (rtPA), which is the current standard practice. Clot dissolving (Fibrinolytic) drugs work to break down blood clots and have been found to improve health outcomes when applied directly into the hematoma within the brain. Patients who take part in this study will undergo the same surgical procedure that would normally be performed to treat them, but with the exception of TNK not rtPA.",[27,256,396],"Hemorrhagic Strokes","2026-04-24",{"date":399,"type":43},"2026-04-30",{"date":401,"type":22},"2026-09-15",{"date":102,"type":22},{"name":404,"class":50},"Gaurav Gupta, MD",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":389,"enrollmentInfo":412,"targetDuration":4,"studyType":140,"phases":414,"briefSummary":415,"conditions":416,"keywords":417,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":51},"100598888","ai-guided-hematoma-aspiration-vs-conservative-treatment-for-spontaneous-ich-100598888","NCT07077343","AI-Guided Hematoma Aspiration vs. Conservative Treatment for Spontaneous ICH","Comparison of AI-assisted Navigated Hematoma Aspiration With Conservative Treatment for Spontaneous Intracerebral Hemorrhage: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Confirmed supratentorial hypertensive intracerebral hemorrhage on brain CT scan\n* Hematoma volume 20-50mL\n* Patients with with GCS score ≥8\n* Admitted within 24h of ictus\n\nExclusion Criteria:\n\n* Intracerebral hemorrhage caused by tumor, coagulopathy, aneurysm, or arteriovenous malformation\n* Concurrent head injury or history of head injury\n* Multiple intracerebral hemorrhage\n* Known advanced demential or disability before\n* Severe concomitant diseases that affect life expectancy\n* With severe intraventricular hemorrhage\n* Pregnant women",{"count":413,"type":22},680,[142],"The effectiveness of traditional craniotomy in the treatment of intracerebral hemorrhage remains controversial. Minimally invasive surgery, specially, image-guided hematoma aspiration, proves to be effective and may have some advantages compared with craniotomy. This multicenter randomized controlled trial aims to evaluate and compare the clinical efficacy of two minimally invasive treatment strategies for patients with spontaneous supratentorial intracerebral hemorrhage (ICH) with moderate hematoma volume (20-50 mL): (1) AI-assisted, navigation-guided hematoma aspiration, and (2) targeted pharmacological therapy. This study is designed to address the current lack of prospective comparative evidence between advanced image-guided surgical intervention and medical management in this specific patient population. By focusing on functional recovery, hematoma resolution, and safety outcomes, this trial seeks to provide high-quality evidence to guide treatment decision-making and optimize individualized care for patients with spontaneous ICH.",[27],[34,418,419,420,421],"navigated hematoma aspiration","conservative treatment","modified rankin scale","artificial intellegience","2026-04-22",{"date":424,"type":43},"2026-04-27",{"date":426,"type":43},"2025-07-01",{"date":428,"type":22},"2031-06-30",{"name":430,"class":50},"Xiaolei Chen",{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":389,"enrollmentInfo":439,"targetDuration":4,"studyType":140,"phases":441,"briefSummary":442,"conditions":443,"keywords":444,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":454},"100610412","phase-3-recombinant-factor-viia-rfviia-for-hemorrhagic-stroke-trial---part-2-100610412","NCT07227246","Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2","Recombinant Factor VIIa (rFVIIa) for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial - Part 2","FASTEST Part 2","Inclusion Criteria:\n\n1. Patients aged 18-80 years, inclusive\n2. Patients with spontaneous ICH\n3. Able to treat with study medication (rFVIIa\u002Fplacebo) within 120 minutes of stroke onset or last known well with a positive spot sign on pretreatment CT angiography or treatment within 90 minutes with or without spot sign.\n4. Efforts to obtain informed consent per EFIC guidelines (U.S.) or adherence to country-specific emergency research informed consent regulations (Canada, Germany, Spain, Finland, U.K., Japan, Australia)\n\nExclusion Criteria:\n\n1. Score of 3 to 7 on the Glasgow Coma Scale\n2. Secondary ICH related to known causes (e.g., trauma, aneurysm, arteriovenous malformation (AVM), oral anticoagulant use (vitamin K antagonists or novel oral anticoagulants) within the past 7 days, coagulopathy, etc.)\n3. ICH volume \\\u003C 2 cc or ≥ 60 cc\n4. Blood filling 2\u002F3 or more of one lateral ventricle of the brain, OR, blood filling at least 1\u002F3 of both lateral ventricles.\n5. Pre-existing disability (mRS \\> 2)\n6. Symptomatic thrombotic or vaso-occlusive disease in past 90 days (e.g., cerebral infarction, myocardial infarction, pulmonary embolus, deep vein thrombosis, or unstable angina)\n7. Clinical or EKG evidence of ST elevation consistent with acute myocardial ischemia\n8. Brainstem location of hemorrhage (patients with cerebellar hemorrhage may be enrolled)\n9. Refusal to participate in study by patient, legal representative, or family member\n10. Known or suspected thrombocytopenia (unless current platelet count documented above 50,000\u002FμL)\n11. Unfractionated heparin use with abnormal PTT\n12. Pro-coagulant drugs within 24 hours prior to patient enrollment into the FASTEST trial (example, tranexamic acid or aminocaproic acid)\n13. Low-molecular weight heparin use within the previous 24 hours\n14. Recent (within 90 days) carotid endarterectomy or coronary or cerebrovascular angioplasty or stenting\n15. Advanced or terminal illness or any other condition the investigator feels would pose a significant hazard to the patient if rFVIIa were administered\n16. Recent (within 30 days) participation in any investigational drug or device trial or earlier participation in any investigational drug or device trial for which the duration of effect is expected to persist until to the time of FASTEST enrollment\n17. Planned withdrawal of care or comfort care measures\n18. Patient known or suspected of not being able to comply with trial protocol (e.g., due to alcoholism, drug dependency, or psychological disorder)\n19. Known or suspected allergy to trial medication(s), excipients, or related products\n20. Contraindications to study medication\n21. Previous participation in this trial (previously randomized)\n22. Females of childbearing potential who are known to be pregnant or within 12 weeks post-partum and\u002For lactating at time of enrollment -",{"count":440,"type":22},350,[301],"The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 90 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include those treated within 2 hours with a positive spot sign on a baseline CT angiogram or patients treated within 90 minutes of stroke onset, with or without a positive spot sign.",[27],[372,445],"recombinant factor VIIa","2026-04-21",{"date":422,"type":43},{"date":449,"type":43},"2025-05-06",{"date":451,"type":22},"2029-06",{"name":453,"class":50},"Joseph Broderick, MD",89,{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":389,"enrollmentInfo":463,"targetDuration":4,"studyType":140,"phases":465,"briefSummary":466,"conditions":467,"keywords":468,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":480},"100618942","phase-3-efficacy-and-safety-of-minocycline-in-acute-spontaneous-intracerebral-hemorrhage-100618942","NCT07338175","Efficacy and Safety of Minocycline in Acute Spontaneous Intracerebral Hemorrhage","Efficacy and Safety of Minocycline in Patients With Acute Spontaneous Intracerebral Hemorrhage: A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase III Trial","MISTICH","Inclusion Criteria:\n\n1. CT-confirmed spontaneous supratentorial intracerebral hemorrhage;\n2. Aged 18 to 80 years;\n3. Within 48 hours of symptom onset;\n4. Hematoma volume 15-40 ml;\n5. NIHSS score 8-24, with item 1a ≤ 2;\n6. Signed informed consent by the patient or legal representative.\n\nExclusion Criteria:\n\n1. Secondary intracerebral hemorrhage (traumatic, tumor-related, vascular malformation, aneurysm, coagulation disorder, etc.);\n2. Intraventricular hemorrhage filling one entire lateral ventricle, third ventricle, or fourth ventricle, or more than half of two lateral ventricles;\n3. Significant subarachnoid hemorrhage (Fisher grade ≥ 3) or subdural hemorrhage;\n4. Patients with uncontrollable hypertension ( systolic blood pressure persistently ≥ 180 mmHg despite intensive antihypertensive treatment);\n5. Progressive neurological or other severe systemic diseases;\n6. Planned surgical intervention for the intracerebral hemorrhage;\n7. Pre-stroke disability (modified Rankin Scale score \\> 1);\n8. Severe cardiac insufficiency (NYHA Class III-IV), severe liver disease (ALT or AST \\> 3 times the normal upper limit value), severe renal insufficiency (serum creatinine \\> 2 times the normal upper limit value, or glomerular filtration rate \\\u003C 45 ml\u002Fmin), or malignancy with life expectancy \\\u003C 1 year;\n9. Moderate to severe anemia (hemoglobin \\\u003C 90 g\u002FL), thrombocytopenia (platelet count \\\u003C 100×10\\^9\u002FL), leukopenia (white blood cell count \\\u003C 2×10\\^9\u002FL), or coagulopathy (INR \\> 1.5);\n10. Allergy or intolerance to minocycline or other tetracycline antibiotics;\n11. History of pseudomembranous enteritis or antibiotic-associated enteritis;\n12. Use of tetracycline antibiotics within the past week;\n13. Intracranial or spinal surgery within the past 3 months;\n14. Any major surgery or severe physical trauma within the past month;\n15. Females who are pregnant, within 30 days postpartum, or in the lactation period.\n16. Participated in other interventional clinical trials within the past 3 months;\n17. Inability to obtain signed informed consent from the patient or representative;\n18. Other conditions that are not suitable for participating in this clinical trial, such as inability to understand and\u002For follow the research procedures due to mental, cognitive, emotional, or physical disorders, etc.",{"count":464,"type":22},1192,[301],"This is a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. It aims to evaluate the efficacy and safety of oral minocycline in patients with acute spontaneous intracerebral hemorrhage within 48 hours of onset.",[27],[27,469,470],"Minocycline","Neuroprotection","2026-04-19",{"date":473,"type":43},"2026-04-23",{"date":475,"type":43},"2026-04-02",{"date":477,"type":22},"2028-12",{"name":479,"class":50},"Beijing Tiantan Hospital",41,{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":487,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":18,"minAge":489,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":140,"phases":492,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":495,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":499,"locationsCount":51},"100357616","phase-3-statins-in-intracerbral-hemorrhage-100357616","NCT03936361","Statins In Intracerbral Hemorrhage","STATINS USE IN INTRACEREBRAL HEMORRHAGE PATIENTS","SATURN","Inclusion Criteria:\n\n1. Age ≥ 50 years.\n2. Spontaneous lobar ICH confirmed by CT or MRI scan\n3. Patient was taking a statin drug at the onset of the qualifying\u002Findex ICH\n4. Randomization can be carried out within 7 days of the onset of the qualifying ICH\n5. Patient or legally authorized representative, after consultation with the statin prescriber, agrees to be randomized to statin continuation (restart) vs. discontinuation\n\nExclusion Criteria:\n\n1. Suspected secondary cause for the qualifying ICH, such as an underlying vascular abnormality or tumor, trauma, venous infarction, or hemorrhagic transformation of an ischemic infarct.\n2. History of recent myocardial infarction (attributed to coronary artery disease) or unstable angina within the previous 3 months\n3. Diabetic patients with history of myocardial infarction or coronary revascularization\n4. History of familial hypercholesterolemia\n5. Patients receiving proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors\n6. Known diagnosis of severe dementia\n7. Inability to obtain informed consent\n8. Patients known or suspected of not being able to comply with the study protocol due to alcoholism, drug dependency, or other obvious reasons for noncompliance, such as unable to adhere to the protocol specified visits\u002Fassessments.\n9. Life expectancy of less than 24 months due to co-morbid terminal conditions.\n10. Pre-morbid mRS \\>3\n11. ICH score \\>3 upon presentation.\n12. Contraindications to continuation\u002Fresumption of statin therapy, such as significant elevations of serum creatinine kinase and\u002For liver transaminases, and rhabdomyolysis\n13. Woman of childbearing potential\n14. Concurrent participation in another research protocol for investigation of experimental therapy.\n15. Indication that withdrawal of care will be implemented for the qualifying ICH.","50 Years",{"count":491,"type":22},1456,[301],"The SATURN trial aims to determine whether continuation vs. discontinuation of statin drugs after spontaneous lobar intracerebral hemorrhage (ICH) is the best strategy; and whether the decision to continue\u002Fdiscontinue statins should be influenced by an individual's Apolipoprotein-E (APOE) genotype.\n\nAn MRI ancillary study (SATURN MRI), in a subset of SATURN participants , will evaluate the effects of continuation vs. discontinuation of statin drugs on hemorrhagic and ischemic MRI markers of cerebral small vessel disease, and whether the presence\u002Fburden of hemorrhagic markers (i.e. cerebral microbleeds and\u002For cortical superficial siderosis) on baseline MRI influences the risk of ICH recurrence on\u002Foff statin therapy.",[27],{"date":446,"type":43},{"date":497,"type":43},"2020-06-10",{"date":332,"type":22},{"name":500,"class":50},"Beth Israel Deaconess Medical Center",{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":389,"enrollmentInfo":509,"targetDuration":4,"studyType":140,"phases":511,"briefSummary":512,"conditions":513,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":178},"100611891","non-invasive-ultrasound-and-hematoma-clearance-after-intracerebral-hemorrhage-100611891","NCT07246473","Non-invasive Ultrasound and Hematoma Clearance After Intracerebral Hemorrhage","Study on the Safety and Efficacy of Non-Invasive Transcranial Doppler Ultrasound in Promoting Hematoma Clearance for Intracerebral Hemorrhage","NOTICE","Inclusion Criteria:\n\n* Age 18 to 80 years;\n* Spontaneous intracerebral hemorrhage (ICH);\n* Supratentorial ICH;\n* Hematoma volume \\\u003C30 mL (calculated using the ABC\u002F2 method);\n* Glasgow Coma Scale (GCS) score \\>9 at randomization;\n* Time from onset to randomization: 48-72 hours;\n* Patient and\u002For legal representative provides informed consent.\n\nExclusion Criteria:\n\n* Intracerebral hemorrhage attributed to other causes (e.g., cerebral aneurysm, cerebrovascular malformation, brain tumor, cerebral venous sinus thrombosis, hemorrhagic transformation of ischemic stroke, head trauma, anticoagulation therapy, hematologic disorders).\n* Hemorrhage located in the infratentorial region.\n* Hemorrhage confined primarily to the ventricular system.\n* Clinical signs or symptoms suggestive of brain herniation (e.g., progressive decline in level of consciousness, diminished or absent pupillary light reflexes, bilateral pyramidal signs).\n* Severe cardiac dysfunction (NYHA Class III or IV).\n* High-risk chronic arrhythmias (e.g., sick sinus syndrome, second- or third-degree atrioventricular block, bradycardia-related syncope without pacemaker implantation).\n* Severe hepatic impairment defined as ALT \\>2x ULN or AST \\>2x ULN (ULN = Upper Limit of Normal).\n* Severe renal impairment defined as serum creatinine \\>1.5x ULN.\n* History of severe asthma or chronic obstructive pulmonary disease (COPD).\n* History of coagulopathy or systemic bleeding disorder.\n* Leukopenia (\\\u003C2 × 10⁹\u002FL) or thrombocytopenia (\\\u003C100 × 10⁹\u002FL).\n* Patients scheduled for surgical intervention (including, but not limited to, hematoma evacuation \\[minimally invasive or conventional\\], decompressive craniectomy, hematoma aspiration, or external ventricular drainage) prior to the first dose of study treatment.\n* Pre-stroke modified Rankin Scale (mRS) score \\>2.\n* Presence of other severe disease resulting in a life expectancy of less than 1 year.\n* Inability to understand the study procedures and\u002For complete follow-up due to psychiatric illness, cognitive impairment, or emotional disorders.\n* Women who are pregnant or lactating.\n* Participation in another clinical trial within the past 3 months or current participation in another clinical trial.",{"count":510,"type":22},86,[142],"Intracerebral hemorrhage (ICH) is one of the stroke subtypes with the highest global rates of disability and mortality, accounting for 15%-20% of all strokes. Currently, there is a lack of evidence-based interventions for ICH, with treatment primarily relying on supportive care. There is an urgent clinical need to explore new strategies and technologies. The investigators hypothesize that for ICH patients, best medical treatment combined with a non-invasive ultrasonic scalpel (ultrasound Doppler flow analyzer) may be superior to best medical treatment alone. The primary objective of this study is to determine the safety and efficacy of the non-invasive ultrasonic scalpel in promoting hematoma clearance in ICH patients.",[27],"2026-04-14",{"date":516,"type":43},"2026-04-17",{"date":518,"type":43},"2025-12-12",{"date":520,"type":22},"2027-12-31",{"name":479,"class":50},{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":18,"minAge":530,"maxAge":389,"enrollmentInfo":531,"targetDuration":4,"studyType":140,"phases":533,"briefSummary":534,"conditions":535,"keywords":537,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":51},"100633557","phase-1-an-open-label-dose-escalation-study-on-the-safety-tolerability-and-preliminary-efficacy-for-preventing-sap-by-intravenous-pump-delivered-propranolol-in-patients-with-ich-100633557","NCT07528235","An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intravenous Pump-Delivered Propranolol in Patients With ICH","An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing Stroke-Associated Pneumonia of Intravenous Pump-Delivered Propranolol in Patients With Intracerebral Hemorrhage","PROCHASE-DoE","Inclusion Criteria:\n\n* Patients aged \\> 18 and ≤ 80 years of age;\n* Can be treated with the study drug within 24 h of symptom onset;\n* No fever or infection was observed upon admission;\n* NIHSS score ≥10;\n* Supratentorial parenchymal haematoma (≥10 mL);\n* GCS score ≥ 6;\n* Patients or their family members sign informed consent forms.\n\nExclusion Criteria:\n\n* Infections within the last 4 weeks;\n* Use of antibiotics within the last 2 weeks;\n* Known pre-ICH dysphagia;\n* Secondary intracerebral hemorrhage or intraventricular hemorrhage resulting from trauma, vascular malformation, aneurysm, coagulopathy, anticoagulant drugs, thrombolysis, post-infarction hemorrhage transformation, hematopathy, moyamoya disease, primary or metastatic tumor, venous sinus thrombosis, vasculitis, and other definite causes;\n* Previous disability with pre-ICH mRS score ≥ 2;\n* Brainstem hemorrhage;\n* Life expectancy less than 14 days;\n* Death appeared imminent;\n* Pregnancy or within 30 d of delivery;\n* Previous use (within 1 month) of β-blockers or reserpine;\n* Bronchial asthma or COPD;\n* Cardiogenic shock;\n* Degree II-III atrioventricular blocks;\n* Severe or acute heart failure;\n* Heart rate \\\u003C 65 beats\u002Fmin;\n* Known to be allergic to propranolol;\n* Severe liver or renal insufficiency;\n* History of malignant tumors;\n* Currently participating in other interventional clinical trials;\n* Currently, immunosuppressants and immunotherapies are being administered.","10 Years",{"count":532,"type":22},30,[393],"This is an open-label, dose-escalation study on the safety, tolerability and preliminary efficacy for preventing stroke-associated pneumonia of propranolol in patients with intracerebral hemorrhage. Propranolol is administered via intravenous pump continuously for 7 days.",[27,536],"Stroke-Associated Pneumonia (SAP)",[538,27,539,540],"Propranolol","Stroke-Associated Pneumonia","Dose-Escalation Study","2026-04-07",{"date":514,"type":43},{"date":544,"type":22},"2026-05-01",{"date":546,"type":22},"2026-11-01",{"name":548,"class":50},"Tang-Du Hospital",{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":553,"acronym":554,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":556,"targetDuration":4,"studyType":140,"phases":558,"briefSummary":559,"conditions":560,"keywords":562,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":572,"locationsCount":178},"100304437","phase-3-avoiding-anticoagulation-after-intracerebral-haemorrhage-100304437","NCT03243175","Avoiding Anticoagulation After IntraCerebral Haemorrhage","A3ICH","Inclusion criteria\n\n* Adult (older than 18 years old, no upper age limit)\n* with a history of paroxysmal, persistent or long-standing non-valvular atrial fibrillation (documented on an electrocardiogram)\n* and a CHA2DS2VASc score of 2 or more who have an indication for long-term anticoagulation\n* who suffered from a spontaneous intracerebral haemorrhage (while being treated with oral anticoagulants or not) documented with brain CT or MRI\n* more than 14 days before randomization (no upper delay limit)\n* for whom there is a clinical equipoise regarding the choice of the best preventive strategy to avoid future vascular events.\n\nExclusion criteria for all treatment groups\n\n* Pre-randomisation modified Rankin score of 4 or 5\n* Conditions other than atrial fibrillation for which the patient requires long term anticoagulation (for example prosthetic mechanical heart valve)\n* Serious bleeding events within the 6 months before randomisation (except for intracerebral haemorrhage)\n* Life expectancy of less than 1 year\n* Pregnancy or breastfeeding\n\nExclusion criteria related to the LAAC only\n\n* Contraindications due to local, anatomical reasons (such as thrombus in the left atrial appendage, infection with a risk of endocarditis)\n* Patients older than 85 years\n* CHA2DS2VASc score of 2 or 3\n* Patient or attending physician are unwilling to undergo\u002Fperform intervention for LAAC\n\nExclusion criteria related to the Direct OAC only\n\n* Chronic renal insufficiency (clearance of creatinine by Cockcroft method \\\u003C 30ml\u002Fmin)\n* Body weight lower than 50 kg\n* Allergy to apixaban\n* Coexisting conditions predisposing to head trauma (e.g. gait disturbances, uncontrolled seizures disorders)\n* Patient or attending physician are unwilling to use of Direct OAC",{"count":557,"type":22},300,[301],"Randomised controlled trials (RCTs) demonstrate a substantial benefit from oral anticoagulant drugs for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (AF). However, these RCTs excluded patients with prior intracerebral haemorrhage (ICH). Therefore, guidelines are unable to recommend whether oral anticoagulant drugs, in particular non-vitamin K antagonist (called direct OAC) - can be used for patients with AF after an intracerebral haemorrhage.\n\nRoughly 30% of adults with ICH have AF but in 2017 it remains unclear whether they should start oral anticoagulant drugs, be treated with left atrial appendage closure (LAAC) or avoid anticoagulation and LAAC.",[27,304,561],"Microhaemorrhage",[34,563,564,565,566],"atrial fibrillation","microhemorrhage","oral anticoagulation","left atrial appendage closure","2026-04-01",{"date":541,"type":43},{"date":570,"type":43},"2019-01-17",{"date":332,"type":22},{"name":269,"class":50},{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":140,"phases":581,"briefSummary":582,"conditions":583,"keywords":587,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":600,"locationsCount":51},"100574015","timing-of-venous-thromboembolism-prophylaxis-in-patients-with-hypertensive-intracerebral-hemorrhage-100574015","NCT06753786","Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage","Early or Delayed Initiation of Venous Thromboembolism Prophylaxis With Heparin in Patients With Hypertensive Intracerebral Hemorrhage","Inclusion Criteria:\n\n* the presence of hypertensive intracerebral hemorrhage\n\nExclusion Criteria:\n\n* Intracerebral hemorrhage expansion detected on the basis of a computed tomography scan of the brain 12-24 hours after a hospital admission (i.e. before the initiation of venous thromboembolism prophylaxis with heparin)\n* Being on an anticoagulant during preadmission period and on day of hospital admission\n* Death within the first 2 days after hospital admission\n* Detection of venous thromboembolism in a patient at the moment of hospital admission\n* Surgical management of hypertensive intracerebral hemorrhage before the beginning of venous thromboembolism prophylaxis using heparin\n* The presence of a malignancy (cancer) in a patient at the moment of hospital admission",{"count":165,"type":22},[142],"The objective of this randomized clinical trial is to evaluate the safety and efficiency of different anticoagulation schemes with heparin for venous thromboembolism prevention in patients with hypertensive intracerebral hemorrhage. The main questions it aims to answer are:\n\n* What is the optimal time for the beginning of anticoagulation with heparin to efficiently prevent venous thromboembolism in patients with hypertensive intracerebral hemorrhage? Early beginning (within the first 2 days but not earlier than 12 hours after the admission of a patient) or delayed beginning (on the third day after the admission of a patient)?\n* Which of the two timeframes (early or delayed) for anticoagulation beginning is the most safe in terms of bleeding complications including intracerebral hemorrhage expansion?\n\nResearchers will compare the results of early and delayed start of anticoagulation using heparin in patients with hypertensive intracerebral hemorrhage to define the optimal start time for anticoagulation that provides the most favourable efficiency\u002Fsafety profile.\n\nParticipants will:\n\n* Undergo a computed tomography (CT) scan of the brain on hospital admission and then 12-24 hours after the hospital admission and 24 hours after the beginning of venous thromboembolism prophylaxis using heparin;\n* Undergo the ultrasound examination of lower extremity deep veins on hospital admission and then once every 7 days;\n* Receive prophylactic doses of low molecular weight heparin or unfractionated heparin either beginning within the first 2 days but not earlier than 12 hours after the hospital admission or starting on the 3rd day after the hospital admission.",[584,585,27,586],"Venous Thromboembolism","Pulmonary Embolism","Deep Vein Thrombosis",[588,589,590,591,372,197,592,593],"Prophylaxis","Deep vein thrombosis","Pulmonary embolism","Venous thromboembolism","Low molecular weight heparin","Unfractionated heparin","2026-03-22",{"date":596,"type":43},"2026-03-24",{"date":598,"type":43},"2024-10-21",{"date":102,"type":22},{"name":601,"class":50},"Pirogov Russian National Research Medical University",{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":608,"eligibilityCriteria":609,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":610,"targetDuration":4,"studyType":140,"phases":612,"briefSummary":613,"conditions":614,"keywords":615,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":635},"100607371","trial-of-early-minimally-invasive-catheter-evacuation-with-thrombolysis-in-intracerebral-hemorrhage-100607371","NCT07187687","TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage","TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage (TIME-ICH): A Prospective, Multi-center, Open-label, Adaptive, Randomized Controlled Trial","TIME-ICH","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Pre-randomization head CT demonstrating an acute, spontaneous, primary ICH;\n3. ICH volume ≥ 20mL as calculated by the ABC\u002F2 method;\n4. The randomization can be completed within 8 hours after the onset of stroke symptoms (or the time last known to be well), and study intervention can reasonably be initiated within 4 hours after randomization.\n5. Historical Modified Rankin Score 0 or 1;\n6. Obtain informed consent from patient or legal representative.\n\nExclusion Criteria:\n\n1. Infratentorial intraparenchymal hemorrhage including midbrain, pontine, or cerebellar;\n2. Ruptured aneurysm, arteriovenous malformation (AVM), vascular anomaly, Moyamoya disease, venous sinus thrombosis, mass or tumor, hemorrhagic conversion of an ischemic infarct, tumor stroke, recurrence of a recent (\\\u003C1 year) ICH, as diagnosed with radiographic imaging;\n3. Presence of spot sign in CT angiography;\n4. Blood pressure control before randomization is ineffective, systolic blood pressure \\> 220 mmHg;\n5. Irreversible impaired brain stem function (bilateral fixed, dilated pupils and extensor motor posturing), GCS ≤ 4;\n6. Hemorrhage with apparent midbrain extension with third nerve palsy or dilated and non-reactive pupils. Other (supranuclear) gaze abnormalities are not exclusions;\n7. Intraventricular extension of the Hemorrhage is visually estimated to involve \\>50% of either of the lateral ventricles;\n8. Any irreversible coagulopathy or known clotting disorder.\n9. Platelet count \\\u003C 750,000, INR \\> 1.4 after correction\n10. Patients requiring long-term anti-coagulation that needs to be initiated \\\u003C 30 days from index ICH;\n11. Use of 2 or more antithrombotic drugs prior to symptom onset;\n12. Patients with a mechanical heart valve;\n13. Positive urine or serum pregnancy test in female subjects without documented history of surgical sterilization or is post-menopausal;\n14. Urokinase allergy;\n15. Any concurrent serious illness that would interfere with the outcome assessments including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, and hematologic disease;\n16. Inability or unwillingness of patient or legal representative to give written informed consent;\n17. Known life-expectancy of less than 6 months;\n18. Participation in a concurrent interventional medical investigation or clinical trial.",{"count":611,"type":22},750,[142],"TIME-ICH (TrIal of early Minimally Invasive catheter Evacuation with thrombolysis in IntraCerebral Hemorrhage) is a multicenter, randomized, adaptive clinical trial comparing best medical management to early minimally invasive surgery with thrombolysis (eMIST) in the treatment of acute spontaneous supratentorial intracerebral hemorrhage.",[27],[27,256,36,616,617,618,619,620,621,622,623,624,625,626],"brain hemorrhage","Hemorrhage","Cerebrovascular Disorders","Brain Diseases","Minimally invasive catheter evacuation","Minimally invasive surgery","Neurosurgery","Thrombolysis","Urokinase","Medical Economic","Hospital Economics","2026-03-06",{"date":629,"type":43},"2026-03-09",{"date":631,"type":43},"2025-10-24",{"date":633,"type":22},"2028-03-01",{"name":104,"class":50},50,{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":642,"eligibilityCriteria":643,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":644,"targetDuration":4,"studyType":140,"phases":646,"briefSummary":647,"conditions":648,"keywords":649,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":653,"startDateStruct":654,"completionDateStruct":655,"leadSponsor":657,"locationsCount":658},"100628226","triple-antihypertensive-medication-after-intracerebral-hemorrhage-for-blood-pressure-control-100628226","NCT07458880","Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control","TRIple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure ConTrol With the TRICH Score","TRIACT","Inclusion Criteria:\n\n1. Spontaneous ICH\n2. Age ≥18 years\n3. Premorbid modified Rankin Scale of ≤3\n4. TRICH score ≥3\n5. Within 1 week of ICH\n\nExclusion Criteria:\n\n1. Glasgow coma score \\\u003C9\n2. Expected life expectancy of six months\n3. Admission SBP \\\u003C160mmHg\n4. Severe renal impairment, estimated glomerular filtration rate using CKD-EPI formula \\\u003C30 ml\u002Fmin\u002F1.73m2\n5. Inability to perform home BP monitoring\n6. Inability to participate in follow-up activity\n7. Hypersensitivity to study drug\n8. Known contraindication to amlodipine\n9. Known contraindication to valsartan\n10. Known contraindication to hydrochlorothiazide\n11. Any conditions that investigator deems that patient is not suitable of any component of the triple pill or antihypertensive medications in general",{"count":645,"type":22},140,[142],"Intracerebral hemorrhage (ICH) is the second most common form of stroke, with an incidence of around 3000 cases per year in Hong Kong. Although it only accounts for around 20-30% of all strokes, ICH is the most severe form of stroke, contributing to 50% of all stroke mortality and the greatest disability burden in stroke. For those who survive their ICH, they are at high risk of ICH recurrence, stroke, cardiovascular event and death. Hence, reducing these risks after ICH is a top priority to lessen the disease's healthcare and social burden.\n\nHypertension is the main driver for ICH, and achieving blood pressure (BP) control significantly reduces the risk of recurrent ICH, stroke and cardiovascular events. However, only 50% of ICH survivors achieved BP control after ICH. This is because ICH patients represent a unique hypertensive population with more difficult-to-control BPs, with many requiring ≥3 antihypertensive medications. Many reasons contribute to uncontrolled hypertension, but inadequate prescription of medication is the most actionable cause. The notion of an upfront prescription of a triple antihypertensive regimen (triple pill) soon after ICH could consequent better BP control, but there are concerns of excessive lowering of BP, particularly in older patients, which has been associated with increased mortality. This approach may also not be suitable for ICH patients with cerebral amyloid angiopathy where the elevated admission BP may be due to acute hypertensive response rather than underlying hypertension. Additionally, the general use of upfront triple pill in all ICH would have healthcare implications, as triple pills are more expensive compared to conventional antihypertensive medications.\n\nTo facilitate individualized treatment, a predictive score, the TRICH score, was recently developed and validated to identify patients who require triple pills after ICH. Therefore, the current TRIACT study aims to test the clinical application and benefit of the TRICH score for the upfront prescription of triple antihypertensive medication after ICH to enable prompt achievement of BP control.",[27],[27,650,651],"Triple antihypertensive medication","Blood pressure control","2026-03-04",{"date":629,"type":43},{"date":377,"type":43},{"date":656,"type":22},"2030-06-30",{"name":381,"class":50},4]